Heparin resistance and antithrombin deficiency;Heparinresistenz und antithrombinmangel

Medizinische Klinik

Volumn 104, Issue 6, 2009, Pages 441-449

  Maurin, Norbert ^a,b  

^a KfH Nierenzentrum   (Germany)

^b KfH Nierenzentrum Neuwied   (Germany)

Author keywords

Activated partial thromboplastin time (aPTT); Anticoagulation; Antithrombin; Asparaginase; Disseminated intravascular coagulation (DIC); Extracorporeal circulation; Heparin resistance

Indexed keywords

ANTITHROMBIN; ASPARAGINASE; DEXAMETHASONE; FIBRINOGEN; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; PROTAMINE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT HIRUDIN; TIROFIBAN; VITAMIN K GROUP;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADD ON THERAPY; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTITHROMBIN DEFICIENCY; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; DRUG RESISTANCE; DRUG TOLERANCE; ENZYME REPLACEMENT; EXTRACORPOREAL OXYGENATION; HEART LUNG MACHINE; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; KIDNEY VEIN THROMBOSIS; LIVER DISEASE; NEPHROTIC SYNDROME; PARTIAL THROMBOPLASTIN TIME; PERITONEUM VEIN SHUNT; PREDICTION; PROTEIN LOSING GASTROENTEROPATHY; REVIEW; SHUNT INFECTION; SHUNT THROMBOSIS; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT INDICATION; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; DRUG RESISTANCE; EXTRACORPOREAL CIRCULATION; EXTRACORPOREAL MEMBRANE OXYGENATION; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; RENAL DIALYSIS; RISK FACTORS; VENOUS THROMBOSIS; WHOLE BLOOD COAGULATION TIME;

EID: 67650757729     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-009-1093-8     Document Type: Review

References (76)

1. S. Alban 2008 Pharmakologie der Heparine und der direkten Antikoagulantien Hämostaseologie 28 400 20
2. S. Alban 2008 Niedermolekulare Heparine - wirklich alle gleich? Vasc Care 15 8 22
3. J.D. Olson C.F. Arkin J.T. Brandt 1998 College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: laboratorymonitoring of unfractionated heparin therapy Arch Pathol Lab Med 122 782 98
4. J. Hirsh K.A. Bauer M.B. Donati 2008 Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practise guidelines (8th edition) Chest 133 Suppl 141S 59S
5. P. Hilbert P. Teumer R. Stuttmann 2008 Thrombembolieprophylaxe auf deutschen Intensivstationen Anaesthesist 57 242 50
6. E.B. Reeve 1980 Steady state relations between factors X, Xa, II, IIa, antithrombin III and alpha-2 macroglobulin in thrombosis Thromb Res 18 19 31 (Pubitemid 10109895)
7. O.R. Odegard M. Lie U. Abildgaard 1975 Heparin cofactor activity measured with an amidolytic method Thromb Res 6 287 94
8. Lechner K. Antithrombinmangel. In: Müller-Berghaus G, Pötzsch B, Hrsg. Hämostaseologie. Berlin-Heidelberg-New York: Springer, 1999:315-20.
9. S.Z. Bucur J.H. Levy G.J. Despotis 1998 Uses of antithrombin in congenital and acquired deficie and antithrombin: should it still be called heparin resistance? J Cardiothorac Vasc Anesth 18 129 30
10. J. Hirsh W.G. van Aken A.S. Gallus 1976 Heparin kinetics in venous thrombosis and pulmonary embolism Circulation 53 691 5
11. A.P. Bode L. Eick 1989 Lysed platelets shorten the activated coagulation time (ACT) of heparinized blood Am J Clin Pathol 91 430 4
12. E. Young M. Prins M.N. Levine 1992 Heparin binding to plasma proteins, an important mechanism for heparin resistance Thromb Haemost 67 639 43
13. D.A. Lane J. Denton A.M. Flynn 1984 Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4 Biochem J 218 725 32
14. J.R. Edson W. Krivit J.G. White 1967 Kaolin partial thromboplastin time: high levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants J Lab Clin Med 70 463 70
15. M.F. Glynn 1979 Heparin monitoring and thrombosis Am J Clin Pathol 71 397 400 (Pubitemid 9188241)
16. H.R. Lijnen M. Hoylaerts D. Collen 1983 Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma J Biol Chem 258 3803 8
17. M.N. Levine J. Hirsh M. Gent 1994 A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin Arch Intern Med 154 49 56 (Pubitemid 24018101)
18. S.T. Hanowell Y.D. Kim V. Rattan 1981 Increased heparin requirement with hypereosinophilic syndrome Anesthesiology 55 450 2
19. A.R. Fisher C.R. Bailey C.N. Shannon 1992 Heparin resistance after aprotinin Lancet II 1230 1
20. J. Col C. Col-Debeys E. Lavenne-Pardonge 1985 Propylene glycol-induced heparin resistance during nitroglycerin infusion Am Heart J 110 171 3
21. M.A. Habbab J.I. Haft 1987 Heparin resistance induced by intravenous nitroglycerin. A word of caution when both drugs are used concomitantly Arch Intern Med 147 857 60
22. L. Pizzulli J. Nitsch B. Lüderitz 1988 Hemmung der Heparinwirkung durch Glyceroltrinitrat Dtsch Med Wochenschr 113 1837 40
23. R.C. Becker J.M. Corrao E.G. Bovill 1990 Intravenous nitroglycerin- induced heparin resistance: a qualitative antithrombin III abnormality Am Heart J 119 1254 61
24. N.E. Lepor D.K. Amin L. Berberian 1989 Does nitroglycerin induce heparin resistance? Clin Cardiol 12 432 4
25. R.A. Schoenenberger L. Menat P. Weiss 1992 Absence of nitroglycerin-induced heparin resistance in healthy volunteers Eur Heart J 13 411 4
26. S.I. Berk A. Grunwald S. Pal 1993 Effect of intravenous nitroglycerin on heparin dosage requirements in coronary artery disease Am J Cardiol 72 393 6
27. O. Muikku 1994 Isosorbide dinitrate does not interfere with heparin anticoagulation: a placebo-controlled comparison with nitroglycerin in patients scheduled for coronary artery surgery Acta Anaesthesiol Scand 38 583 6
28. S.Y. Nottestad A.M. Mascette 1994 Nitroglycerin-induced heparin resistance: absence of interaction at clinically relevant doses Mil Med 159 569 71
29. N. Maurin 1995 Heparin-induzierte Thrombozytopenie Intensiv Notfallbehandlung 20 93 7
30. A. Greinacher 1995 Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis Semin Thromb Hemost 21 106 16
31. A. Greinacher S. Alban M.A. Omer-Adam 2008 Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the different immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings Thromb Res 122 211 20
32. E.F. Anderson 1986 Heparin resistance prior to cardiopulmonary bypass Anesthesiology 64 504 7
33. M.M. Samama 1995 Laboratory monitoring of unfractionated heparin treatment Clin Lab Med 15 109 17
34. M. Ranucci G. Isgro A. Cazzaniga 1999 Predictors for heparin resistance in patients undergoing coronary artery bypass grafting Perfusion 14 437 42
35. A. Bauters C. Zawadzki A. Bura 1996 Homozygous variant of antithrombin with lack of affinity for heparin: management of severe thrombotic complications associated with intrauterine fetal demise Blood Coagul Fibrinolysis 7 705 10
36. P.G. Langley R.D. Hughes A. Forbes 1993 Controlled trial of antithrombin III supplementation in fulminant hepatic failure J Hepatol 17 326 31
37. Pötzsch B, Madlener K. Gerinnungskonsil. Rationelle Diagnostik und Therapie von Gerinnungsstörungen. Berlin-Heidelberg-New York: Springer, 2002.
38. V.M. Shami S.H. Caldwell E.E. Hespenheide 2003 Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy Liver Transpl 9 138 43
39. P.R. Atkison L. Jardine S. Williams 2005 Use of recombinant factor VIIa in pediatric patients with liver failure and severe coagulopathy Transplant Proc 37 1091 3
40. G. Ramsey 2006 Treating coagulopathy in liver disease with plasma transfusions or recombinant factor VIIa: an evidence-based review Best Pract Res Clin Haematol 19 113 26
41. M.G. Mazzucconi L. Gugliotta G. Leone 1994 Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase Blood Coagul Fibrinolysis 5 23 8
42. L.G. Mitchell M. Andrew K. Hanna 2003 Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia. Results of the PARKAA study Thromb Haemost 90 235 44
43. M. Hunault-Berger P. Chevallier M. Delain 2008 Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study Haematologica 93 1488 94
44. F. Llach 1985 Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome Kidney Int 28 429 39
45. R. Bellomo R.C. Atkins 1993 Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted? Nephron 63 249 54
46. R.J. Glassock 2007 Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum J Am Soc Nephrol 18 2221 5
47. B.L. Warren A. Eid P. Singer 2001 High-dose antithrombin III in severe sepsis JAMA 286 1869 78
48. J. Kienast M. Juers C.J. Wiedermann 2006 Treatment of high-dose antithrombin without concomitant heparin in patients with severe sepsis with and without disseminated intravascular coagulation J Thromb Haemost 4 90 7
49. N. Maurin 1990 Therapie der disseminierten intravasalen Gerinnung (DIC) Therapiewoche 40 3332 5
50. N. Maurin 2007 Substitution von Antithrombin bei manifester disseminierter intravasaler Gerinnung (DIC) Med Welt 58 328 32
51. F.B. Taylor C.H. Toh W.K. Hoots 2001 Towards definition, clinical and laboratory criteria, and scoring system for disseminated intravascular coagulation Thromb Haemost 86 1327 30
52. Bundesärztekammer. 2008 Bekanntmachung: Querschnitts-Leitlinien (BÄK) zur Therapie mit Blutkomponenten und Plasmaderivaten Dtsch Ärztebl 105 A2121
53. Bundesärztekammer, Hrsg. Querschnitts-Leitlinien (BÄK) zur Therapie mit Blutkomponenten und Plasmaderivaten, 4. Aufl. Köln: Deutscher Ärzte-Verlag, 2009.
54. G. Guyatt H.J. Schünemann D. Cook 2004 Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 Suppl 179S 87S
55. G.H. Guyatt D.J. Cook R. Jaeschke 2008 Grades of recommendation for antithrombotic agents: American College of Chest Physicians evidence-based clinical practise guidelines (8th edition) Chest 133 Suppl 123S 31S
56. H.R. Büller J.W. ten Cate 1983 Antithrombin III infusion in patients undergoing peritoneovenous shunt operation: failure in the prevention of disseminated intravascular coagulation Thromb Haemost 49 128 31
57. J. Bharadwaj C. Jayaraman R. Shrivastava 2003 Heparin resistance Lab Hematol 9 125 31
58. W.J. DeBois J. Liu B. Elmer 2006 Heparin sensitivity test for patients requiring cardiopulmonary bypass J Extra Corpor Technol 38 307 9
59. M.S. Avidan J.H. Levy J. Scholz 2005 A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass Anesthesiology 102 276 84
60. M.R. Williams A.B. D'Ambra J.R. Beck 2000 A randomized trial of antithrombin concentrate for treatment of heparin resistance Ann Thorac Surg 70 873 7
61. B.D. Spiess 2008 Treating heparin resistance with heparin or fresh frozen plasma Ann Thorac Surg 85 2153 60
62. A. Koster T. Fischer M. Gruendel 2003 Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation J Cardiothorac Vasc Anesth 17 171 5
63. J.H. Lemmer G.J. Despotis 2002 Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery J Thorac Cardiovasc Surg 123 213 7
64. M. Ranucci G. Isgro A. Cazzaniga 2002 Different patterns of heparin resistance: therapeutic implications Perfusion 17 199 204 (Pubitemid 34467126)
65. J.M. Rodriguez-Lopez E. del Barrio F.S. Lozano 2008 Does preoperative level of antithrombin III predict heparin resistance during extracorporeal circulation? Anesth Analg 107 1444 5
66. G.J. Despotis M. Avidan J.H. Levy 2007 Heparin resistance and the potential impact on maintenance of therapeutic coagulation Eur J Anaesthesiol 24 Suppl40 37 58 (Pubitemid 47066004)
67. A.B. Kelly S.R. Hanson L.W. Henderson 1989 Prevention of heparin-resistant thrombotic occlusion of hollow-fiber hemodialyzers by synthetic antithrombin J Lab Clin Med 114 411 8
68. D. du Cheyron B. Bouchet C. Bruel 2006 Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study Crit Care 10 R45
69. M. Lafargue O. Joannes-Boyau P.M. Honore 2008 Acquired deficit of antithrombin and role of supplementation in septic patients during continuous veno-venous hemofiltration ASAIO J 54 124 8
70. R. Kopp D. Henzler R. Dembinski 2004 Extrakorporale Membranoxygenierung beim akuten Lungenversagen Anaesthesist 53 168 74
71. B. Mejak C. Giacomuzzi I. Shen 2005 Cardiopulmonary bypass using argatroban as an anticoagulant for a 6.0-kg pediatric patient J Extra Corpor Technol 37 303 5
72. R.A. Esposito A.T. Culliford S.B. Colvin 1983 Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment J Thorac Cardiovasc Surg 85 346 53
73. S. Bar-Yosef H.B. Cozart B. Phillips-Bute 2007 Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery Can J Anaesth 54 107 13
74. G.J. Despotis A.L. Alsoufiev Spitznagel 1996 Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses Ann Thorac Surg 61 795 9
75. G.J. Despotis V. Levine J.H. Joist 1997 Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation Anesth Analg 85 498 506 (Pubitemid 27381298)
76. E. Young P. Wells S. Holloway 1994 Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin Thromb Haemost 71 300 4